P42336 (PK3CA_HUMAN) Homo sapiens (Human)

Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform UniProtKBInterProSTRINGInteractive Modelling

1068 aa; Sequence (Fasta) ; 13 identical sequences

Available Structures

106 Experimental Structures

DescriptionPDB IDOligo-stateRangeSeq id (%)Ligands
PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 12). Heteromer
P27986;
1-1068
99.911LT;YQB;
Crystal Structure of PI3Kalpha Heteromer
P27986;
3-1065
99.81PO4;GOL;
Crystal Structure of PI3Kalpha in complex with the inhibitor NVP-BYL719 Heteromer
P27986;
3-1065
99.811LT;NA;
PI3Ka H1047R co-crystal structure with inhibitors in two cryptic pockets (compounds 4 and 5). Heteromer
P27986;
2-1064
99.9YO4;YOR;YNZ;
PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 4). Heteromer
P27986;
2-1064
99.9YO4;YNZ;
STX-478, a Mutant-Selective, Allosteric Inhibitor bound to H1047R PI3Kalpha Heteromer
P27986;
2-1063
99.910×EDO;X3N;ZWE;
Discovery of imidazo[1,2-a]-pyridine inhibitors of pan-PI3 kinases that are efficacious in a mouse … Heteromer
P27986;
2-1062
100.0GOL;5XV;
Crystal structure of human T1061E PI3Kalpha in complex with its regulatory subunit and the inhibito… Heteromer
P27986;
2-1062
99.9MWF;EDO;PGE;CL;
p110alpha/p85alpha with compound 5 Heteromer
P23727;
2-1062
100.05H2;
Co-crystal Structures of the Lipid Kinase PI3K alpha with Pan and Isoform Selective Inhibitors Heteromer
P27986;
2-1061
100.0SCN;1LT;
Crystal Structure of a novel tetrahydropyrazolo[1,5-a]pyrazine in an engineered PI3K alpha Heteromer
P27986;
2-1061
99.83K6;
Co-crystal Structure of Lipid Kinase PI3K alpha with a selective phosphatidylinositol-3 kinase alph… Heteromer
P27986;
2-1061
100.04Q2;
STX-478, a Mutant-Selective, Allosteric Inhibitor bound to PI3Kalpha Heteromer
P27986;
2-1061
100.0X3N;ZWE;
Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha and the drug wortman… Heteromer
P27986;
5-1062
99.9KWT;
Crystal structure of PI3K alpha with PI3K delta inhibitor Heteromer
P27986;
2-1059
100.06CY;
PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket (compound 5). Heteromer
P27986;
2-1059
99.9YOR;YNZ;
Crystal structure of p110alpha H1047R mutant in complex with niSH2 of p85alpha Heteromer
P27986;
5-1062
99.9
The co-structure of (R)-4-(6-(1-(cyclopropylsulfonyl)cyclopropyl)-2-(1H-indol-4-yl)pyrimidin-4-yl)-… Heteromer
P27986;
2-1057
99.418DV;
Crystal Structure of PI3Kalpha in complex with fragment 23 Heteromer
P27986;
1-1056
100.0SOA;
Structure of p110alpha/niSH2 - vector data collection Heteromer
P27986;
2-1057
100.0144;SO4;
Crystal Structure of PI3Kalpha in complex with fragment 10 Heteromer
P27986;
3-1058
100.071N;
Crystal Structure of PI3Kalpha in complex with fragments 6 and 24 Heteromer
P27986;
1-1054
100.070W;70V;CL;
Crystal Structure of PI3Kalpha in complex with fragments 17 and 27 Heteromer
P27986;
1-1054
100.071A;71B;
Crystal Structure of PI3Kalpha in complex with fragment 22 Heteromer
P27986;
1-1054
100.071F;
Crystal Structure of PI3Kalpha in complex with fragments 19 and 28 Heteromer
P27986;
1-1054
100.071G;ES3;
Co-structure Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform complex… Heteromer
P27986;
2-1054
99.59ZUO;
Crystal structure of PI3Kalpha in complex with fragments 7 and 11 Heteromer
P27986;
1-1053
100.0EPE;70S;FB1;
Crystal Structure of PI3Kalpha in complex with fragments 12 and 15 Heteromer
P27986;
2-1054
100.071M;LUZ;
Crystal Structure of PI3Kalpha in complex with fragment 14 Heteromer
P27986;
1-1053
100.071L;
Co-structure of Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform and … Heteromer
P27986;
2-1053
99.59ZTV;SO4;
Crystal Structure of p110alpha complexed with niSH2 of p85alpha and PI-103 Heteromer
P27986;
8-1059
100.0X6K;SO4;GOL;
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
8-1059
100.084R;P6G;SO4;GOL;
The co-structure of N,N-dimethyl-4-[(6R)-6-methyl-5-(1H-pyrrolo[2,3- b]pyridin-4-yl)-4,5,6,7-tetrah… Heteromer
P27986;
2-1053
99.413K6;
The co-structure of 3-amino-6-(4-((1-(dimethylamino)propan-2-yl)sulfonyl)phenyl)-N-phenylpyrazine-2… Heteromer
P27986;
2-1053
99.48DY;
Crystal Structure of PI3Kalpha in complex with fragments 5 and 21 Heteromer
P27986;
1-1052
100.0AX7;CAQ;
Crystal Structure of PI3Kalpha in complex with fragments 20 and 26 Heteromer
P27986;
1-1052
100.0718;CL;SAL;
Crystal Structure of PI3Kalpha in complex with fragment 13 Heteromer
P27986;
5-1056
100.071J;
Crystal Structure of PI3Kalpha in complex with fragments 4 and 19 Heteromer
P27986;
1-1052
100.0CL;70T;2ZV;
Crystal Structure of PI3Kalpha in complex with fragment 18 Heteromer
P27986;
1-1052
100.071K;
PI3K alpha in complex with an inhibitor Heteromer
P27986;
2-1052
100.0KVJ;
Crystal Structure of p110alpha complexed with niSH2 of p85alpha Heteromer
P27986;
8-1058
100.0SO4;
Crystal Structure of PI3Kalpha in complex with fragment 8 Heteromer
P27986;
2-1052
100.0URF;
Crystal Structure of PI3Kalpha in complex with diC4-PIP2 Heteromer
P27986;
4-1053
100.0PBU;PO4;
Human PI3K p85alpha/p110alpha H1047R bound to compound 2 Heteromer
P27986;
2-1050
99.9UIW;
Crystal Structure of PI3Kalpha in complex with fragment 29 Heteromer
P27986;
3-1051
100.0BHO;
PI3Ka H1047R co-crystal structure with inhibitor in cryptic pocket near H1047R (compound 7). Heteromer
P27986;
2-1049
99.9YQ2;1LT;
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
8-1055
100.084U;GOL;SO4;
Crystal structure of PI3K complex with an inhibitor Heteromer
P27986;
8-1055
100.084X;SO4;
Crystal Structure of PI3Kalpha in complex with fragment 9 Heteromer
P27986;
4-1051
100.0HPP;
Crystal Structure of p110alpha in complex with niSH2 of p85alpha Heteromer
P27986;
6-1052
100.0
Crystal Structure of p110alpha complexed with niSH2 of p85alpha and compound 9d Heteromer
P27986;
8-1053
100.0XXK;SO4;GOL;
Human PI3K p85alpha/p110alpha H1047R bound to compound 3 Heteromer
P27986;
5-1050
99.9UJC;
PI 3-kinase alpha with nanobody 3-142, crosslinked with DSG Heteromer
P27986;
6-1051
100.0
Human PI3K p85alpha/p110alpha bound to RLY-2608 Heteromer
P27986;
5-1049
100.0XUZ;
Human PI3K p85alpha/p110alpha H1047R bound to compound 1 Heteromer
P27986;
6-1050
99.9UE9;
Cryo-EM structure of PI3Kalpha in complex with compound 18 Heteromer
P27986;
7-1050
100.0L2V;
Cryo-EM structure of PI3Kalpha in complex with compound 16 Heteromer
P27986;
7-1050
100.07TZ;
Cryo-EM structure of PI3Kalpha in complex with compound 17 Heteromer
P27986;
7-1050
100.07U5;
Cryo-EM Structure of p110alpha in complex with p85alpha Heteromer
P27986;
7-1050
100.0
Structure of a human p110alpha/p85alpha complex Heteromer
P27986;
8-1050
100.0
Human PI3K p85alpha/p110alpha bound to compound 2 Heteromer
P27986;
8-1050
100.0UIW;
Human PI3K p85alpha/p110alpha Heteromer
P27986;
11-1051
100.0
PI 3-kinase alpha with nanobody 3-142 Heteromer
P27986;
19-1059
100.0
p85alpha/p110alpha heterodimer H1047R mutant Heteromer
P27986;
11-1047
99.9
PI 3-kinase alpha with nanobody 3-126 Heteromer
P27986;
20-1053
100.0
Cryo-EM structure of p110alpha in complex with p85alpha inhibited by BYL-719 Heteromer
P27986;
18-1050
100.01LT;
Cryo-EM structure of cancer-specific PI3Kalpha mutant H1047R in complex with BYL-719 Heteromer
P27986;
19-1050
99.91LT;
CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-7909 binding at an allosteric site Heteromer
P27986;
19-1050
99.9UEX;
CryoEM structure of PI3Kalpha Heteromer
P27986;
22-1053
100.0
PI 3-kinase alpha with nanobody 3-159 Heteromer
P27986;
26-1056
100.0
CryoEM structure of human PI3K-alpha (P85/P110-H1047R) with QR-8557 binding at an allosteric site Heteromer
P27986;
21-1050
99.9UJ3;
Crystal structure of HLA-A*03:01 in complex with a mutant PIK3CA peptide Heteromer
P04439; P61769;
1046-1054
88.89GOL;FMT;
Crystal structure of HLA-A*03:01 in complex with a wild-type PIK3CA peptide Heteromer
P04439; P61769;
1046-1054
100GOL;
Crystal structure of human 0606T1-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide Heteromer
P04439; P61769;
1046-1054
88.8913×GOL;
Crystal structure of human 21LT2-2 TCR bound to HLA-A*03:01 in complex with a mutant PIK3CA peptide Heteromer
P04439; P61769;
1046-1054
88.89ACT;GOL;
Pi3K alpha lipid kinase with Active Site Inhibitormonomer2-1052
100.04EL;
HUMAN PI3KDELTA IN COMPLEX WITH COMPOUND 2Fmonomer107-1052
100.0VBS;
Crystal structure of PI3K-alpha in complex with taselisibmonomer107-1051
100.0799;
Human PI3Kalpha in complex with Compound 2-10 ((3S)-3-benzyl-3-methyl-5-[5-(2-methylpyrimidin-5-yl)…monomer107-1051
100.0P5J;GOL;
p110alpha with GDC-0326monomer107-1051
100.05H5;EDO;
Crystal structure of PI3K-alpha in complex with compound 19monomer107-1051
100.0X3W;
Crystal structure of PI3K-alpha in complex with compound 32monomer107-1051
100.0X3N;
Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazol…monomer107-1051
100.0FE5;
Crystal structure of PI3K-alpha in complex with compound 30monomer107-1051
100.0X3R;
Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-4-chloro-1-isopropyl-1…monomer107-1051
100.0FDH;
Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-1H-pyrazol…monomer107-1051
100.0FDW;
Crystal structure of PI3K alpha in complex with 3-(2-Amino-benzooxazol-5-yl)-1-isopropyl-4-methyl-1…monomer107-1051
100.0FCZ;
CRYSTAL STRUCTURE OF PI3K ALPHA IN COMPLEX WITH A 7-(3-(PIPERAZIN-1-YL)PHENYL)PYRROLO[2,1-F][1,2,4]…monomer107-1050
100.085S;
Cryo-EM structure of cancer-specific PI3Kalpha mutant E545K in complex with BYL-719monomer107-1050
99.881LT;
Cryo-EM structure of cancer-specific PI3Kalpha mutant E542K in complex with BYL-719monomer107-1050
99.881LT;
Crystal structure of the p110alpha catalytic subunit from homo sapiens in complex with activator 19…monomer107-1047
99.89QIH;
Crystal structure of the apo p110alpha catalytic subunit from homo sapiensmonomer107-1046
100.0
Isolated p110a subunit of PI3Ka provides a platform for structure-based drug designmonomer107-1046
100.0
Discovery of a potent and isoform-selective targeted covalent inhibitor of the lipid kinase PI3Kalp…monomer107-1046
100.0KKR;
Isolated p110a subunit of PI3Ka provides a platform for structure-based drug designmonomer107-1046
100.0ML9;
Crystal structure of human PI3Ka (p110a subunit) with MMV085400 bound to the active site determined…monomer107-1046
100.0ZHY;
PQR530 [(S)-4-(Difluoromethyl)-5-(4-(3-methylmorpholino)-6-morpholino-1,3,5-triazin-2-yl)pyridin-2-…monomer107-1046
100.0M1J;
Crystal structure of PI3Kalpha selective Inhibitor PF-06843195monomer109-1047
100.0VXY;
Structure of p110 alpha bound to (S)-1-(4-((2-(4-(4-(2-amino-4-(difluoromethyl)pyrimidin-5-yl)-6-(3…monomer107-1045
100.0RNX;
Structure of PIK3CA with covalent inhibitor 19monomer107-1045
100.02Q7;
Structure of PIK3CA with covalent inhibitor 22monomer107-1045
100.02IX;
Crystal structure of PI3Kalpha inhibitor 10-5429monomer109-1045
100.0VY1;
Crystal structure of PI3Kalpha selective Inhibitor 11-1575monomer109-1045
100.0VY4;
Crystal structure of PI3Kalpha inhibitor 4-0686monomer109-1044
100.0VYP;
Solution structure of the C2 domain from human PI3-kinase p110 subunit alphamonomer331-481
100
Crystal structure of PI3K-alpha Ras Binding Domain (RBD)monomer157-300
100.0

2 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
4l2y.1.Amonomer0.858-1053
XXK;100.00
5sxj.1.Amonomer0.843-1051
100.00